First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics is a U.S.-based clinical-stage biotechnology company focused on developing antibody therapies for autoimmune and inflammatory diseases. Its wholly owned pipeline includes ANB033, rosnilimab, and ANB101, which are being advanced as potential treatments for immune-mediated conditions.

— First Tracks Biotherapeutics, Inc.
%
Clinical-stage antibody therapeutics100% Antibody drug candidates in human clinical development for autoimmune and inflammatory diseases.

The company does not sell commercial products today; its primary counterparties are clinical investigators, trial...

  • Clinical development ecosystemprimary

    Hospitals, investigators, and regulators involved in running and reviewing trials for ANB033, rosnilimab, and ANB101.

  • Autoimmune disease patientsprimary

    Patients who could eventually receive approved therapies for celiac disease, eosinophilic esophagitis, rheumatoid arthritis, or related immune disorders.

  • Biopharma collaboratorssecondary

    Potential partners that may support development, licensing, or commercialization of the pipeline.

First Tracks Biotherapeutics is headquartered in the United States and operates as a U.S...

  • •Headquartered in the United States
  • •Clinical development is centered in the U.S. public-company structure
  • •Patent protection may span multiple jurisdictions
  • •Future commercialization could expand into major pharma markets
  • •Geographic exposure is driven by trial sites, IP, and approvals

The company’s strategy is to advance a focused set of antibody programs through clinical development and build value...

01
Advance clinical-stage pipelineshort-term

Clinical data are the main value driver for a biotechnology company without commercial products.

02
Establish independent operating structureshort-term

Separation from the former parent requires standalone systems, governance, and capital allocation.

03
Protect and extend intellectual propertymedium-term

Patent coverage is central to exclusivity and future commercial value in biopharma.

The company faces the core risks of clinical-stage biotechnology: programs may fail in development, trial results may...

critical

Clinical development failure or delay

The company depends on successful trial progression to create value and reach commercialization.

Scope
ANB033, rosnilimab, ANB101
Materiality
high
high

Safety or tolerability issues in trials

Adverse events can reduce regulatory approval odds and market acceptance.

Scope
All pipeline programs
Materiality
high
high

Spin-off and separation execution risk

Standalone operations require new systems, allocations, and transitional support from the former parent.

Scope
Separation and Distribution Agreement; TSA
Materiality
medium
high

Intellectual property risk

Biopharma value depends on patent scope, enforceability, and duration.

Scope
Owned and licensed patent portfolio
Materiality
high
Related-party cost allocations
Affects comparability of operating expenses and margins
Transition Services Agreement accounting
Can distort near-term expense trends
Development-stage accrual estimates
Can move quarterly R&D expense
Emerging growth company reporting
May reduce comparability with larger peers

SAB Biotherapeutics, Inc.

SABS · Biological Products, (No Diagnostic Substances)

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Glucotrack, Inc.

GCTK · Surgical & Medical Instruments & Apparatus

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Coya Therapeutics, Inc.

COYA · Pharmaceutical Preparations

: 16/06/2026